Health & Wellness Community

Pharmacists working in government hospitals will now be required to provide medications in envelopes with dosage instructions written in the local language. The objective of this measure is to enhance patient safety, ensure quality assurance, and prevent medication errors. The new policy applies to all patients seeking treatment at government hospitals. Due to the high patient volume, doctors in these hospitals may not always have sufficient time to explain dosage instructions and timings to each patient individually. Additionally, medical prescriptions are typically written in English, which many patients receiving care at government hospitals may not understand. As per the new directive, pharmacists from the hospital’s dispensary will be responsible for writing the names of the medicines, along with their dosages and timings, in the local language on a stamped format that includes the hospital’s name. A health official stated that this initiative aims to promote the safe and appropriate use of medications.

AIIMS in New Delhi has successfully implemented a new app called ABHA, which stands for Ayushman Bharat Health Account, aimed at reducing waiting times and long queues for Outpatient Department (OPD) patients. The implementation of this app has yielded impressive results, with AIIMS issuing a total of 73,700 ABHA-based scan and share OPD tokens to date, securing the hospital’s position as a leader in providing efficient and patient-centric healthcare services. The ABHA mobile application has significantly improved the patient experience by streamlining the registration process and reducing waiting times. Previously, patients had to endure long queues at OPD registration counters, causing discomfort and inconvenience. However, with the introduction of the ABHA-based scan and share facility, patients can now easily bypass these queues by scanning a designated QR code and receiving a unique token number. When their token is displayed, they can directly approach the counter without waiting in line. By embracing this advanced technology, AIIMS New Delhi demonstrates its commitment to utilizing digital solutions for the benefit of its patients. Dr. M Srinivas, the Director of AIIMS New Delhi, expressed his enthusiasm for the positive impact of this technology on patient care, emphasizing the institution’s goal of continuously improving the patient experience. The introduction of the ABHA-based Scan and Share facility is part of AIIMS New Delhi’s ongoing commitment to innovation and excellence in healthcare delivery, as they strive to provide a world-class healthcare experience.

Pfizer’s respiratory syncytial virus (RSV) vaccine for older adults has been approved by the US Food and Drug Administration (FDA), becoming the second vaccine against this common respiratory disease to receive approval. The FDA’s decision closely follows the approval of a similar vaccine by GSK Plc. Pfizer’s vaccine, named Abrysvo, is authorized for individuals aged 60 and older, matching the age group for GSK’s vaccine. According to a late-stage study, Pfizer’s vaccine demonstrated 67% effectiveness among adults aged 60 and older with two or more RSV symptoms and 85.7% efficacy against severe illness characterized by three or more symptoms. Both Pfizer and GSK anticipate a lucrative market for RSV vaccines. Pfizer aims to make its vaccine available in the third quarter before the next RSV season, pending approval from the US Centers for Disease Control and Prevention (CDC). The CDC’s advisory committee is scheduled to convene in June to discuss various aspects, including the target recipients and dosing intervals for the vaccines. Pfizer has not disclosed the price of the vaccine but has stated that it will be value-based to support routine vaccination within the recommended age group. If the CDC recommends routine use, the vaccine will likely be widely accessible at no cost for most older Americans covered by the Medicare health plan. Although RSV typically causes mild cold-like symptoms, it can lead to severe illness and hospitalization, particularly among individuals aged 65 and older, resulting in approximately 14,000 deaths annually in the United States. Furthermore, Pfizer is pursuing FDA approval for its RSV vaccine to protect infants by vaccinating pregnant women. If approved, it would be the first RSV vaccine available for safeguarding babies, who face a high risk of severe illness. The vaccine has received support from the FDA’s external expert panel for use in pregnant women. Pfizer plans to launch its RSV vaccine for older adults and pregnant women in the United States and Europe this year. Moderna Inc also intends to seek approval for its RSV vaccine targeting individuals aged 60 and older later this quarter. In November, Sanofi and AstraZeneca gained European marketing authorization for their antibody treatment nirsevimab, designed to prevent RSV in newborns and infants, and it is currently undergoing FDA review.

Chemicals and Fertilisers Minister Mansukh Mandaviya announced plans to introduce the Product Linked Incentive (PLI) scheme for fundamental chemicals on Friday and urged the pharmaceutical and medical device sector to concentrate on producing high-quality goods at competitive prices to compete globally. The minister stated that Modi government is “pro-poor, pro-farmers but also industry-friendly” when speaking at an international conference on the pharmaceutical and medical device industries. He also stated that all policies are being developed following extensive talks with the industry and other stakeholders. Mandaviya emphasised that India is the “pharmacy of the world” and that the sector needs to concentrate on research and developments as well as be aware of global development in order to maintain its position as a leader. He stated that the sector should be prepared for international competition. Mandaviya stated that in order to succeed in the global marketplace, companies must “bring affordability, and do quality manufacturing.” “We have to advance our reputation with affordability and quality. Bargaining with quality damages our world-class reputation. I do not want to tolerate that,” he said. He urged industry support for the government’s initiatives to ensure the quality of the pharmaceutical and medical device industries. “Any negligence in the quality will prove to be detrimental in the global competition,” the minister stated, adding that he does not wish to take harsh measures on the industry. The government has introduced PLI-I and PLI-II initiatives for this industry, according to Mandaviya, to increase domestic production and exports while also making it more self-sufficient. According to Mandaviya, “in the coming days, we are coming up with PLI scheme for basic chemicals also,” based on the industry’s feedback. Mandaviya emphasised the need for research and development in this industry and urged MSMEs working in it to make advantage of government facilities that have been made available to everyone. The minister published the National Medical Devices Policy 2023 and its strategy document prior to his speech. Additionally, he established the Medical Devices Export Promotion Council. The “Assistance to Medical Device Clusters For Common Facilities (AMD-CF)” scheme was also launched by Mandaviya.

The COVID-19 pandemic, according to Prime Minister Narendra Modi, has shown numerous weaknesses in the global health infrastructure. He also underlined that concerted action is required to create resilience in global systems. While India demonstrated its commitment to international cooperation by sending nearly 300 million vaccine doses to more than 100 countries, Modi said the pandemic also highlighted the need to improve global health equity in his video message to the 76th session of the World Health Assembly in Geneva, Switzerland. “Many of these countries were from the Global South. I am sure that supporting equal access to resources will be a top priority for the WHO in the coming years,” he said. Modi stated that during the past five years, India has strived to improve the availability, usability, and affordability of healthcare. An approach that takes into account the scope of India’s diversity can also serve as a model for others, he said. We are eager to help the WHO with similar initiatives in low- and middle-income nations. The prime minister stated that many of India’s efforts are geared at improving health at the last mile, whether it is through the world’s largest health insurance programme, Ayushman Bharat, or the vast expansion of health facilities, or the drive to bring sanitation and drinking water to millions of people. He added that ancient practises like yoga, ayurveda, and meditation address the physical, mental, and social facets of health. According to India’s traditional thinking, being free of illness does not equate to being in good health. He expressed his happiness that India would soon be home to the first Global Centre for Traditional Medicine of the WHO. The International Year of Millets is another thing that makes me pleased because it shows how important millets are to the world. Modi emphasised that the globe is viewed as a single family in India’s ancient scriptures. “During our G20 Presidency this year, we are working with the theme of ‘One Earth, One Family, One Future’. Our vision for good health is ‘One Earth One Health’. We can be healthy only when our whole ecosystem is healthy. So, our vision is not restricted to just humans. It extends to the entire ecosystem, including animals, plants and the environment,” he said.

According to the National Medical Commission’s (NMC) new regulations, doctors must get a Unique Identification Number (UID) in order to practise medicine in the nation. The NMC ethics board will centrally generate the UID, which will thereafter grant the practitioner registration in NMR and the right to practise medicine in India. A common national medical register will be maintained for all of the nation’s licenced medical professionals, according to the most recent NMC announcement. The Ethics and Medical Registration Board (EMRB) of the NMC will maintain the same. All entries for registered medical practitioners from all State Registers kept by the various State Medical Councils will be included in this record, together with all pertinent information on the practitioner. The “Registration of Medical Practitioners and Licence to Practise Medicine Regulations, 2023” new notification stated that the license to practise medicine granted to a registered medical practitioner will be valid for a period of five years after which the medical practitioner will have to renew the license by submitting an application to the State Medical Council. It said that applications for licence renewal may be submitted up to three months before the license’s validity expires.

At the summit of world leaders next week, the Group of Seven (G7) rich countries are expected to decide to launch a new program to provide vaccines to developing nations, according to a report on Saturday in Japan’s Yomiuri newspaper. The World Health Organisation (WHO), the World Bank, and G20 countries like India will also join, it was stated, citing sources from the Japanese government. The COVAX facility, supported by WHO and the Global Alliance for Vaccines and Immunization (GAVI), provided emerging nations with over 2 billion doses of coronavirus vaccine during the COVID-19 pandemic. COVAX faced challenges in guaranteeing fair access, however, as wealthy countries prioritised vaccinations for their citizens, while insufficient storage facilities in poorer countries resulted in supply delays and the disposal of millions of doses that were close to expiration. According to the publication, the new program aims to pool rainy-day funds for vaccine manufacturing and purchases, as well as investments in low-temperature storages and training of healthcare professionals in preparation for the next pandemic. In order to counter the rising power of China and Russia, Japan, this year’s G7 summit chair, seeks to gain support from emerging nations on a variety of topics, including supply chains, food security, and climate change.

The World Bank has approved $82 million in funding to support the prevention and control of zoonotic diseases in India. Zoonotic diseases are illnesses that can be transmitted from animals to humans, such as rabies, avian influenza, and leptospirosis. The project aims to strengthen India’s health systems and surveillance mechanisms to better detect and respond to zoonotic diseases. This will include the development of a national One Health platform, which will bring together experts in human, animal, and environmental health to better understand and prevent the spread of zoonotic diseases. “In India, around 68 per cent of the workforce relies on farming and remains in close contact with domestic animals and poultry, thereby becoming frequently exposed to sick or infected animals,” said Hikuepi Katjiuongua, Adarsh Kumar and Anupam Joshi, the Task Team Leaders for the program. The project will also support the development of rapid response teams, laboratory networks, and community-based surveillance systems. The funding will be provided over a period of five years and will be implemented by the Indian government’s Ministry of Health and Family Welfare.

IOL Chemicals and Pharmaceuticals has been granted a Certificate of Suitability by the European Directorate for the Quality of Medicines and Healthcare (EDQM) to export paracetamol to the European market. One of the top pharmaceutical (APIs) firms and a prominent player in the market for specialty chemicals, a listed company was established in 1986. Paracetamol is widely used in medications prescribed for pain relief and fever treatment. The pharma firm informed stock exchanges on Monday that, “The certification issued by the EDQM verifies the compliance of pharmaceutical substances and with this backing, IOL will now be able to export paracetamol to the European continent.” In 2022, the company’s Punjab-based factory will begin commercial production of paracetamol. It can currently produce 3,600 tonnes of paracetamol in total. The UK, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, the United States, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, United Arab Emirates, China, Hong Kong, and Egypt are the nations where it has consumers abroad.

At a meeting on May 16, the government plans to reopen discussions with industry stakeholders on the divisive subject of trade margin rationalisation (TMR) on drugs and medical devices. Members of pharmaceutical associations and makers of medical devices were invited to the meeting in this respect by the Department of Pharmaceuticals (DoP) and the National Pharmaceutical Pricing Authority (NPPA), who also requested suggestions by Friday. “The DoP and NPPA have been receiving various suggestions from the industry for amendments in DPCO, 2013 and National Pharmaceutical Pricing Policy. Hence, it has been decided to organise a workshop with industry stakeholders with the participation of the associations of pharma and the medical device sector,” said the invite. The lobby group members are anticipated to start the conversation of implementing TMR on pharmaceutical formulations. The government should implement the “one-molecule, one-price” formula, according to several small and medium-sized pharmaceutical companies.